Back

Inhibrx advances ozekibart with 52% lower chondrosarcoma progression risk

Verifying
  • Inhibrx is progressing ozekibart and INBRX-106 cancer treatments.
  • Ozekibart reduced chondrosarcoma progression risk by 52%.
  • Ozekibart showed strong responses in colorectal and Ewing sarcoma.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.